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SUMMARY  16 
 17 
Regulation of c-Src activity by the intrinsically disordered Unique domain has been 18 
recently demonstrated. However, its connection with the classical regulatory 19 
mechanisms is still missing. Here we show that the Unique domain is part of a long 20 
loop closed by the interaction of the SH4 and SH3 domains. The conformational 21 
freedom of the Unique domain is further restricted through direct contacts with SH3 22 
that are allosterically modulated by binding of a poly-proline ligand in the presence 23 
and in the absence of lipids. Our results highlight the scaffolding role of the SH3 24 
domain for the c-Src N-terminal intrinsically disordered regions and suggest a 25 
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 2 
connection between the regulatory mechanisms involving the SH3 and Unique 26 
domains.  27 
 28 
INTRODUCTION 29 
 30 
The non-receptor protein kinase c-Src was the first discovered proto-oncogene and it 31 
plays a critical role in mediating signal transduction in multiple pathways (Martin, 32 
2001) related with cell migration, invasion and survival, all of which contribute to its 33 
oncogenic potential. High levels of c-Src activity have been associated to poor 34 
prognosis in colorectal, prostate and breast cancers (Sirvent et al., 2012; Yeatman, 35 
2004; Hynes, 2000). However, c-Src mutations are seldom found in cancer cells, 36 
suggesting that the transforming potential is associated to failures in c-Src 37 
regulation.  38 
c-Src domain structure, which is shared with the other members of the Src family of 39 
kinases (SFKs), consists of four “Src-homology” domains: SH4, SH3, SH2 and SH1, 40 
arranged in this order from the N-terminus to the C-terminus, with the “Unique” 41 
domain separating the SH4 and SH3 domains (Figure 1A). The SH1 domain is the 42 
enzymatically active kinase domain. The SH4 domain contains lipid substitutions and 43 
is primarily responsible for anchoring the SFKs to membranes. In the case of c-Src it 44 
contains a myristoyl group attached to the N-terminus. Positively charged residues in 45 
the SH4 domain also contribute to the interaction with negatively charged 46 
membranes (Resh, 1999). The Unique domain is intrinsically disordered and also 47 
has the capacity to interact with lipids, other proteins, such as calmodulin, and the 48 
adjacent SH3 domain (Perez et al., 2013).  49 
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 3 
The SH3 and SH2 domains are regulatory domains. The interaction of the SH2 50 
domain with a phosphorylated tyrosine located near the C-terminus contributes to 51 
maintain c-Src in a closed basal state that is enzymatically inactive. The viral forms 52 
of Src (v-Src) missing the C-terminal tyrosine are constitutively active (Martin, 2001) 53 
but various v-Src forms display different levels of activity indicating additional levels 54 
of regulation (Reddy et al., 1990; Brábek et al., 2002). Structurally, the Y530F mutant 55 
of human c-Src remains 85% in its closed form (Bernadó et al., 2009). This second 56 
layer of regulation has been associated to interactions involving the SH3 domain, 57 
including binding to a proline-rich region in the linker connecting the SH2 and SH1 58 
domains (Xu et al., 1999), as well as interactions not related to poly-proline binding 59 
and involving the nSrc and RT-loops (Brábek et al., 2002).  60 
SH3 domains are one of the most abundant domain families in eukaryotes, with 61 
about 300 occurrences in the human genome (Karkainen et al., 2006). SH3 domains 62 
are small (60-70 residues) and consist in a -sandwich formed by five or six -63 
strands connected by three loops (the RT, nSrc and distal loops) and a short 310 64 
helix (Figures 1B, 1C).  65 
In addition to the canonical interaction with PxxP sequences (Cheadle et al., 1994; 66 
Rickles et al. 1994; Feng et al., 1995), the SH3 domain of c-Src interacts with lipids 67 
and the Unique domain (Perez et al., 2013). The SH3 residues directly interacting 68 
with PxxP segments and the Unique domain are located in opposite sides of the 69 
domain. However, binding of a high affinity poly-proline peptide to the SH3 domain 70 
allosterically modulates the interaction with the Unique domain (Perez et al., 2013).  71 
The functional role of the Unique domain has remained obscure until very recently. 72 
Residues 60-67 in the Unique domain form the Unique lipid binding region (ULBR) 73 
(Figure 1B) with residual structure even in the isolated domain (Perez et al., 2009). 74 
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 4 
Lipid binding was abolished by replacing residues 63-65 (LFG) by three alanines 75 
(Perez et al., 2013). This mutation, which we refer to as AAA, causes strong 76 
phenotypes when introduced in full-length c-Src and expressed in Xenopus laevis 77 
oocytes (Perez et al., 2013) or in human colorectal cancer cells (unpublished).  78 
These results strongly suggest that the Unique domain forms a new layer of 79 
regulation for c-Src but raise the question of how this new regulation mechanism is 80 
connected with the classical ones, involving the SH3 and SH2 domain. Figure 1A 81 
summarizes the previously and newly described regulatory interactions and 82 
highlights the central role of the SH3 domain. In this work we show the SH3 domain 83 
acting as scaffold for the intrinsically disordered Unique domain, the interaction 84 
between the SH3 and the SH4 domains closing a long loop including the entire 85 
Unique domain, the direct interaction of the SH3 domain with lipids, and the allosteric 86 
modulation of SH3 binding to the Unique domain and lipids by its canonical 87 
interaction with a poly-proline peptide. 88 
 89 
RESULTS 90 
 91 
Interaction of SH3 with the Unique and SH4 domains of c-Src 92 
 93 
NMR chemical shift perturbations (CSP) were used to map the residues affected by 94 
the interaction between SH3 and the disordered regions of c-Src (USrc = SH4 + 95 
Unique domains). They were determined by comparing 1H-15N HSQC NMR spectra 96 
of a linked multi-domain construct (USrc-SH3, residues 1-150) with those of shorter 97 
peptides, containing the individual components (USrc, residues 1-85; SH3, residues 98 
86-150). The peptides and proteins used are summarized in Table 1. Figure 2 shows 99 
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 5 
the sequence-specific combined 15N and 1H CSP measured at pH 7.0. Figure 2A 100 
shows the results for the disordered regions measured at 278 K to minimize proton 101 
amide exchange. Disregarding amino acids close to the linkage region (83-89), T37, 102 
A55, E60, K62 and N68 in the Unique domain and K5, S6 in the SH4 domain are the 103 
most affected residues. Residues 2 to 4 are not observable due to fast exchange at 104 
this pH and temperature. Figures 2B show the SH3 residues whose chemical shifts 105 
are affected by the presence of the Unique and SH4 domains at 298 K. The main 106 
changes in the SH3 domain are observed in the nSrc loop, around V114, and the RT 107 
loop (R98, D102). Perturbations are also observed in residues around H125 and 108 
T132 flanking the distal loop, and in residues located in the 310 helix and the C-109 
terminal region.  110 
SH3 domains recognize poly-proline sequences. The binding site is formed mainly 111 
by aromatic residues on the SH3 surface (highlighted in Figures 1B and 1C) but  112 
ligand binding effects propagate across the SH3 domain through a hydrogen bond 113 
network, (Wang et al., 2001; Cordier et al., 2000) extending to the RT-loop and 114 
residues located on the opposite side of the poly-proline ligand binding site. We had 115 
previously reported the allosteric modulation of Unique domain binding by the 116 
addition of a poly-proline peptide (PPP) with the sequence Ac-VSLARRPLPPLP-OH, 117 
which is a consensus high affinity SH3 ligand (Perez et al., 2013; Feng at al., 1995). 118 
Interestingly, the interaction between the SH3 domain and residues in the SH4 119 
domain is not affected by the presence of the PPP ligand. This is clearly seen in 120 
Figure 2C in which similar large chemical shifts differences for residues K5 and S6 121 
are observed between USrc and USrc-SH3 in the presence and in the absence of 122 
PPP. In contrast, many of the Unique domain residues that were most affected by 123 
the interaction with the SH3 domain (T37, A55, E60, K62) have very similar chemical 124 
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 6 
shift values in USrc and USrc-SH3 in the presence of the PPP ligand, indicating that 125 
those amino acids sense an environment similar to that of USrc.   126 
Chemical shifts differences of SH3 residues in the SH3-PPP complex and in the 127 
USrc-SH3-PPP complex map the regions of the SH3 domain that are interacting with 128 
USrc in the presence of the PPP ligand. Figure 2D clearly shows that the interactions 129 
involving the nSrc loop are retained, while most of the other interacting regions 130 
disappear in the SH3-PPP complex. Since only the N-terminal region of the SH4 131 
domain retains its interaction in the presence of PPP it can be concluded that this 132 
region of the SH4 domain interacts with the nSrc loop of SH3 in the SH3-PPP 133 
complex. The similar chemical shifts of residues K5 and S6 in the apo and PPP-134 
bound forms of USrc-SH3 suggest that these residues are also interacting with the 135 
nSrc loop in the apo protein, and that the RT-loop interacts with the Unique domain 136 
in the absence of the PPP ligand but this interaction is lost in the PPP complex. The 137 
regions of the SH3 domain interacting with the disordered domains in the absence 138 
and in the presence of PPP are indicated in Figures 2E and 2F.  139 
The USrc region is covalently connected to the SH3 domain but also anchored to the 140 
SH3 domain by the N-terminal part of the SH4 domain closing a 78-residues long 141 
loop including the remaining residues of the SH4 domain and the complete Unique 142 
domain. Additional contacts between residues in the Unique domain and SH3 further 143 
decrease its conformational freedom. The contacts with the Unique domain are lost 144 
in the PPP complex but a flexible loop is retained. The chemical shifts of NH groups 145 
of residues in the hinge region connecting the SH3 and Unique domains (residues 146 
S75-G85) are clearly affected by PPP binding to SH3 probably reflecting local 147 
changes caused by the loss of interactions along the Unique domain affecting the 148 
overall loop geometry.  149 
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 150 
The Unique domain directs the interaction site of SH4 in the SH3 domain  151 
 152 
The interaction between the SH4 and SH3 domains was confirmed using a synthetic 153 
peptide with the sequence of the SH4 domain (SH4 peptide, residues 2-19, 154 
GSNKSKPKDASQRRRSLE).  155 
Figure 3A shows the chemical shifts perturbations induced by the addition of a 10-156 
fold excess of SH4 peptide to 100 M SH3. In this experiment the most perturbed 157 
residues are located in the RT-loop, with the charged residues R98, E100 most 158 
affected. Additional effects are observed in residues located or flanking the distal 159 
loop (H125, G130, T132), with minor effects observed in the nSrc loop. The nSrc 160 
loop is the most perturbed region of the SH3 domain when the SH4 and SH3 161 
domains are connected by the Unique domain, both in the presence and in the 162 
absence of PPP peptide. The addition of SH4 peptide to the complex formed 163 
between SH3 and PPP, induces chemical shift changes in the RT loop that are much 164 
smaller than in the case of apo-SH3 (Figure 3C). However, the effects in the nSrc 165 
and distal loop are similar and very small, in contrast to the large chemical shift 166 
changes in the nSrc loop observed when the PPP complexes of SH3 and USrc-SH3 167 
are compared (Figure 2D). Thus, the Unique domain facilitates the interaction 168 
between the SH4 and nSrc loop both in the apo forms, where the Unique domain 169 
directly interacts with the SH3 domain, and in the PPP complex, where the direct 170 
Unique-SH3 interaction is lost.  171 
The capacity of a 78-residue flexible peptide chain to determine the interaction site of 172 
the SH4 domain is a surprising result, considering the intrinsically disordered nature 173 
of the Unique domain. Previous NMR studies of the USrc protein had confirmed its 174 
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 8 
intrinsically disordered nature but had identified a short segment between residues 175 
60 and 75 with residual structure (Perez et al., 2009). We decided to use a 176 
previously designed mutant, (Perez et al., 2013) in which residues 63-65 (LFG) had 177 
been replaced by alanines (AAA) to investigate the effects of Unique domain residual 178 
structure.  179 
 180 
The AAA Unique domain mutant retains the interactions with the SH3 domain 181 
 182 
Figure 4 shows plots of sequence dependent chemical shift differences obtained by 183 
comparing USrc-SH3-AAA, USrc-AAA and SH3 following the same approach used 184 
for the wild type construct (cf. Figure 2).  185 
The perturbations induced by the WT and AAA forms of USrc in the NH chemical 186 
shifts of SH3 residues are similar. In particular, residues around V114, in the nSrc 187 
loop are the most perturbed also in the AAA mutant (cf. Figures 2B and 4B). The RT 188 
loop is also affected, although R98 and D102 show smaller chemical shift changes 189 
than in the wild-type construct. Small reductions on the chemical shift changes are 190 
also observed in the other loops although, overall, the same regions are affected.  191 
USrc residues outside the mutation site show a very similar perturbation profile in the 192 
WT and AAA forms (cf. Figures 2A and 4A), confirming that the AAA mutation 193 
preserves most of the interaction sites between the Unique and SH3 domains, 194 
although the overall interaction is weaker.  195 
Chemical shift differences may originate from direct contacts or indirect effects. To 196 
confirm the interaction between the Unique and SH3 domains we used 197 
Paramagnetic Relaxation Enhancement (PRE) by a paramagnetic centre (MTSL) 198 
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 9 
attached to a cysteine residue introduced at position 59 (close to the ULBR) of the 199 
WT and AAA mutants of USrc-SH3 constructs.  200 
Proximity of the unpaired electron centre induces fast relaxation of the NMR signals, 201 
which translates into line broadening and decreased intensity. A reference spectrum 202 
is obtained by reducing the spin-label with an excess of ascorbic acid. Results are 203 
presented as the intensity ratio between the oxidized and reduced samples.  204 
Figure 5 compares the PRE effects of a spin-label located at position 59 of the 205 
Unique domain in WT and AAA USrc-SH3. The most affected regions in the SH3 206 
domain (highlighted) are similar. Residues in the distal loop and the RT-loop are less 207 
affected by the spin label in the AAA mutant than in the WT, in agreement with the 208 
chemical shift perturbation results. 209 
  210 
Long-range intra-domain contacts in the Unique domain are perturbed in the 211 
AAA mutant  212 
 213 
PRE effects on NH signals of peaks within the Unique domain show a complex 214 
pattern indicative of long-range contacts that is different for the WT and AAA 215 
proteins. In order to focus on the interactions within the USrc region, independently 216 
of additional interactions with the SH3 domain, we measured PREs in the isolated 217 
WT and AAA forms of USrc (Figures 6A, 6B). The PRE pattern as a function of the 218 
position along the sequence in the WT protein is not compatible with that expected 219 
for a random coil, indicated by the continuous grey line. Deviations from the 220 
predictions of the ideal-random coil model are lower in the AAA mutant than in WT 221 
USrc, suggesting that residues replaced by the AAA mutation have a direct influence 222 
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in the restricted conformational space (as compared to a random coil) sampled by 223 
the isolated Unique domain.  224 
 225 
Lipid binding by USrc-SH3: de-convoluting lipid and inter-domain interactions 226 
using PPP binding  227 
 228 
The SH3 domain binds to lipids through the RT- and nSrc loops. The affected 229 
residues are the same in the isolated SH3 domain (Perez et al., 2013), USrc-SH3 230 
WT and USrc-SH3 AAA (Figure S1).  231 
Since PPP binding to SH3 affects the RT-loop, we tested its effect on lipid binding. 232 
Figures 7A and 7B show the result of adding DHPC-DMPG bicelles in the NH 233 
chemical shifts of the apo- and PPP-bound forms of USrc-SH3. PPP binding nearly 234 
completely abolished direct lipid interaction of the SH3 domain but preserved those 235 
of residues 64-67 (ULBR) and 14-17 in the C-terminal part of the SH4 domain.  236 
However, while the chemical shifts of NH groups from ULBR residues of USrc-SH3 237 
in the presence of PPP but without lipids are the same as in USrc, the corresponding 238 
chemical shifts of the USrc-SH3-PPP complex in the presence of lipids do not 239 
coincide with those of USrc bound to lipids. These observations suggest that, 240 
although direct interaction of the ULBR with the SH3 domain is lost in the PPP 241 
complex, lipid binding by the ULBR is affected by the proximity of the SH3 domain.  242 
This observation is consistent with the retention of the interaction of the SH4-SH3 243 
interaction in the PPP complex.  244 
Residues T37 and K62 interact with apo-SH3 but not with lipids. In the PPP complex 245 
these residues show the same chemical shift as in USrc confirming that PPP 246 
abolishes the direct interaction of the Unique and SH3 domains also in the presence 247 
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of lipids. The chemical shifts of residues A55 and E60 in the absence of PPP are 248 
affected by the addition of lipids (Figures 7B, S2) and also by the interaction with the 249 
SH3 domain (Figure 2A). In the PPP complex, both interactions are abolished. Thus 250 
PPP binding prevents the lipid interaction of residues 55 and 60 but not that of the 251 
ULBR. Residues 72 and 78 are perturbed by the addition of lipids only in the PPP 252 
complex. Considering that these residues are close to the Unique domain-SH3 hinge 253 
region, it is unclear whether the observed chemical shift changes represent direct 254 
lipid interactions or variations in the conformation of the hinge region induced by the 255 
interaction of the SH4 and ULBR with the lipid surface.  256 
Figures 7C and 7D show the effect of adding PPP to USrc-SH3 in the presence of 257 
bicelles. Residues in the hinge region (72-85) are also strongly perturbed by PPP 258 
binding (Figure 7C). Those residues experience chemical shift perturbations of the 259 
same order as those observed by USrc-SH3-PPP binding in the absence of lipids 260 
(Figure 2C) suggesting that the 78-residue loop formed by the interaction between 261 
the SH4 and SH3 domains is preserved in the presence of lipids and its 262 
conformational space is affected when the additional contacts with the Unique 263 
domain are eliminated in the PPP complex.  264 
Chemical shifts of the SH4 and SH3 residues that are mutually interacting in the 265 
absence of lipids are a good monitor for the persistence of this interaction. For 266 
example, the absence of chemical shift changes upon addition of PPP indicates that 267 
the SH3-SH4 interaction in conserved. The addition of PPP has the further effect to 268 
eliminate direct interactions between the SH3 and lipids. Therefore, the absence of 269 
chemical shifts in the SH3 region of USrc-SH3-PPP complex in the presence of lipids 270 
(Figure 7B) is an additional indication of the conservation of the Unique domain loop. 271 
Similarly, the chemical shifts of residues 6 and 7 of the SH4 domain in the presence 272 
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of lipids and PPP are very similar to those observed in the absence of lipids 273 
confirming that the SH4-SH3 interaction is preserved in the presence of lipids.  274 
The SH4 domain is known to be the primary anchoring site of c-Src to membranes 275 
but we have shown that also interacts with the SH3 domain. This raises the question 276 
of how SH4 binding to lipids and the SH3 domain affect each other.  277 
The SH4 domain includes the first 19 residues of c-Src. However, from our data, it 278 
appears to be composed of two regions (nSH4 and cSH4). Residues 5-7 (and 279 
possibly the preceding, not observed residues) form the N-SH4 sub-domain that 280 
binds the SH3 domain and are only marginally affected by lipids (at least in the not-281 
myristoylated constructs). Residues 12-17 constitute the cSH4 sub-domain that 282 
shows the largest perturbations in the presence of negatively charged lipids (Figure 283 
7A). In the USrc-SH3-PPP complex the interaction of cSH4 residues with lipids is 284 
maintained (and extended to include A21 in the Unique domain, Figure 7B). The 285 
chemical shifts of nSH4 residues are less affected by lipids and show similar 286 
changes in the apo and PPP-bound forms. The observed lipid-induced shifts in nSH4 287 
may indicate that either this region is simultaneously interacting with lipids and the 288 
SH3 domain, or that they are affected by changes in the lipid-binding mode of the 289 
neighbour cSH4 sub-domain. In any case, the SH4 domain as a whole 290 
simultaneously interacts with lipids and the SH3 domain.  291 
Interestingly, the boundary between nSH4 and cSH4 includes D10, the only 292 
negatively charged residue in the strongly positive charged domain. This residue 293 
together with its first neighbour A11, are not observable in the NMR spectra of USrc-294 
SH3-PPP complex in presence of bicelles, probably due to exchange broadening as 295 
is often observed in hinge regions.  296 
 297 
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DISCUSSION 298 
 299 
c-Src regulation through inter-domain interactions involving the folded SH2, SH3 and 300 
kinase domain, as well as the regulatory C-terminal tail has been extensively 301 
studied. The SH4 domain is mainly associated to the capacity of c-Src to interact 302 
with lipids, while the role of the intrinsically disordered Unique domain remains poorly 303 
understood, in spite of recent findings (Perez et al., 2013).  304 
Here we have shown that the RT, nSrc and distal loops in the SH3 domain play a 305 
key role in the conformational properties of the flexible SH4 and Unique domain. We 306 
have also shown that binding of a poly-proline ligand to the SH3 domain allosterically 307 
affects the interactions involving the RT and nSrc SH3 loops, and therefore, directly 308 
influences the confomational space sampled by the Unique domain. Figure 8 shows 309 
a cartoon representation summarizing the contacts between the SH4, Unique and 310 
SH3 domains in absence and presence of lipids as well as the effect of PPP binding 311 
to the SH3 domain or the AAA mutation in the Unique domain.   312 
The regulatory role of the Unique domain has been demonstrated by the phenotipic 313 
effects caused by the introduction of the AAA mutation in the full length protein 314 
expressed in a constitutively active form in Xenopus laevis oocytes and in colorectal 315 
SW620 cancer cells (unpublished). Regulatory inputs may include the known 316 
interactions of the Unique domain with lipids, with calmodulin (Perez et al., 2013), or 317 
its phosphorylation at various serine and threonine sites (Perez et al., 2009; Amata 318 
et al., 2013). How these imputs are converted in changes in the kinase activity or 319 
selectivity remains to be understood. The SH3 domain seems to be playing the role 320 
of an interaction hub connecting the flexible SH4 and Unique regions with the folded 321 
domain (SH1, SH2, SH3) cluster.  322 
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Independent evidence supporting the connection between the SH3 and Unique 323 
domains can be found by comparing the sequences of various v-Src forms (Table 324 
S1) in which, in addition to the missing regulatory tail, simultaneous mutations in the 325 
ULBR and the RT-loop of the SH3 domain are observed. These data are in 326 
agreement with the present NMR study indicating that the Unique domain 327 
preferentially interacts with the RT-loop.  328 
The flexible SH4 and Unique domains of c-Src sample a restricted conformational 329 
space determined by long-range interactions including the SH3 domain. Ligand 330 
binding to the SH3 domain allosterically modulates some of these interactions but 331 
intra-domain contacts within the Unique domain are also important. The AAA 332 
mutation, which was experimentally observed to cause strong phenotypes when 333 
introduced in full-length c-Src, reduces some of these interactions leading to a more 334 
random-coil type conformation in the Unique domain. The same mutation destroys 335 
the Unique domain lipid binding region (Perez et al., 2013) but does not substantially 336 
modify the interactions of the Unique and SH4 domains with SH3 even in presence 337 
of a poly-proline peptide (Figure S3). Therefore, perturbation of the lipid binding 338 
remains the most probable mechanisms for the phenotypic effects of the AAA full-339 
length mutant, although more subtle effects, related to its perturbation of the Unique 340 
domain conformational space cannot be ruled out.  341 
Binding of a poly-proline ligand to the SH3 domain induces an allosteric regulation of 342 
the interactions involving the RT loop. Two of these interactions have been 343 
observed: binding of lipids by the SH3 domain and the interaction with the Unique 344 
domain. Interestingly, the interaction between the SH4 and SH3 domains in the 345 
USrc-SH3 construct is not affected by ligand binding and, therefore, the Unique 346 
domain is not completely released, although the direct contacts with the SH3 domain 347 
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are lost. This mechanism is conserved even when the molecule is interacting with 348 
lipid membranes. Thus, the SH3 domain remains close to the Unique domain and to 349 
the lipid surface even though the direct interactions with lipids or the Unique domain 350 
are lost. In the inactive form of c-Src the SH3 domain interacts with the proline rich 351 
segment connecting the SH2 and SH1 domains. This interaction is at least partially 352 
released when c-Src is activated. With the observed allosteric effects of PPP 353 
binding, is tempting to speculate on the possible “reverse” signalling in which the 354 
activation state of c-Src is transmitted to the flexible Unique and SH4 domains 355 
modulating their interaction with lipids.  356 
 357 
EXPERIMENTAL PROCEDURES 358 
 359 
Cloning and mutagenesis 360 
The cDNA encoding for human c-Src SH4 and Unique domains (USrc, residues 1-361 
85) plus a C-terminal Strep-tag® (SAWSHPQFEK) inserted for purification purposes, 362 
was cloned into a pET-14b vector (Novagene, UK). The human c-Src SH3 domain 363 
construct (SH3, residues 86-150) or bound to the c-Src N-terminal region (USrc-364 
SH3, 1-150) was cloned into a pETM-30 vector (EMBL) after a TEV cleavage site 365 
and expressed as His6-GST fusion proteins. Site-directed mutations were introduced 366 
using the QuikChange™ mutagenesis kit (Stratagene). 367 
 368 
Protein expression and purification 369 
The plasmids carrying the proteins of interest were transformed in Escherichia coli 370 
RosettaTM(DE3)pLysS cells (Novagen, UK). Cells were grown in M9 minimal medium 371 
supplemented with 15N (15NH4Cl from Cambridge Isotope Laboratories, UK). Protein 372 
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expression was carried out at 25ºC overnight after induction with 1 mM IPTG. Cells 373 
were then harvested and sonicated. USrc protein was purified from the cell lysate 374 
using Strep-tactin sepharose resin (IBA, Germany) and eluted with 2.5 mM of 375 
desthiobiotin. His6-GST-SH3 and His6-GST-USrc-SH3 constructs were recovered 376 
from cell lysate with Ni-NTA resin (Qiagen, Netherlands) and eluted with 400 mM 377 
imidazole. An overnight digestion with His-tagged TEV protease was performed at 378 
4°C in order to remove the GST tag-protein. Imidazole was then removed from 379 
solution using PD-10 desalting columns (GE Healthcare, Spain). Digested products 380 
were incubated again with Ni-NTA resin at RT for 1hr. The flow-through containing 381 
only the protein of interest was collected. 382 
Further purification was performed with size exclusion chromatography in a 383 
Superdex 75 26/60 column (GE Healthcare). For USrc constructs, 50 mM sodium 384 
phosphate buffer, 0.2 mM EDTA and 0.01% NaN3 at pH 7.0 was used. For SH3 and 385 
USrc-SH3, the buffer was 50 mM sodium phosphate, 150 mM NaCl, 0.2 mM EDTA 386 
and 0.01% NaN3 at pH 7.5. The protein-containing fractions were pooled, 387 
concentrated to the desired concentration (Centricon 5 kDa, Millipore, USA) and 388 
stored at 4ºC. 389 
Further details about USrc purification protocols are described in Perez et al. (Perez 390 
et al., 20132). Synthetic peptides SH4 and PPP were added as 40mM stock solutions 391 
in MilliQ H2O to minimize dilution effects upon addition to the NMR samples. 392 
 393 
NMR spectroscopy 394 
After purification, all 15N labelled samples were dissolved in 50 mM sodium 395 
phosphate buffer at pH 7.0 with 90% H2O / 10% D2O. Protein concentrations were in 396 
the range of 0.2 - 0.3 mM in all measurements.  397 
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All experiments were performed in a Bruker 600 MHz Advance III spectrometer 398 
equipped with a TCI cryoprobe (Unitat de RMN, Universitat de Barcelona, Spain). 399 
Either 1H-15N HSQC or 1H-15N SOFAST-HMQC (Schanda at al., 2005) experiments 400 
were carried out at pH 7.0 at 278 K, optimum for observing Unique domain signals, 401 
or 298 K, better suited to observe the SH3 domain and samples with lipid bicelles. 402 
NMR spectra were processed using Bruker TopSpinTM 3.0 and NMRPipe (Delaglio et 403 
al., 1995), and analysed using Sparky (Goddard and Kneller).  404 
Combined chemical shift differences were calculated following the equation: 405 
Δδ = [(ΔδH)2 + (ΔδN/5)2] 1 / 2               Equation 1 406 
Individual chemical shifts differences larger than one standard deviation from the 407 
mean of all measured differences in the relevant pair of spectra were considered 408 
statistically significant.  409 
USrc and USH3 assignments had been previously reported (Perez et. al., 2009; 410 
Perez et al., 2013). SH3 backbone assignment in presence of a poly-proline peptide 411 
was based on literature values (BRMB 4889) measured at pH 6.5 and 298 K.  412 
Molecular images were generated using VMD 1.9.2 (Humphrey et al., 1996) or 413 
Chimera  (Pettersen et al., 2004).  414 
 415 
PRE experiments 416 
The paramagnetic tag used for spin labelling was MTSL ((1-oxy-2,2,5,5-tetramethyl-417 
D-pyrroline-3-methyl)-methanethiosulfonate). The cysteine-containing mutants were 418 
purified following the same previously described protocol with 5 mM DTT on each 419 
step to avoid disulphide-bond formation. For protein-tagging reaction, DTT was 420 
removed using a desalting PD-10 column and a 16-fold excess of MTSL was added 421 
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to the protein solution. After overnight reaction at 4ºC, the MTSL excess was 422 
eliminated using a desalting column.  423 
Addition of a 5-fold excess of ascorbic acid to the protein solution was used to 424 
reduce the nitroxide radical and provided the control diamagnetic sample. 425 
Theoretical PRE profiles were calculated using Flexible Meccano 1.1 (Ozenne et al., 426 
2012). 50,000 conformer ensembles were generated for each construct. The intrinsic 427 
1H linewidth parameter was obtained from the average linewidth of the 1H signals in 428 
the diamagnetic sample. 429 
 430 
Lipid bicelle preparation 431 
Negatively charged bicelles were prepared using a mixture of short chain (DHPC, 432 
dihexanoyl phosphatidylcholine) and long chain (DMPG, dimyristoyl phosphatidyl 433 
glycerol) lipids in a molar ratio of 1.0 DHPC : 0.8 DMPG (q = 0.8, 44.4% DMPG 434 
molar ratio), which provides isotopic fast tumbling bicelles (Glover et al., 2001; Vold 435 
et al., 1997). The lipids were dissolved in chloroform mixtures and the solvent was 436 
evaporated in vacuo. The resulting lipid film was rehydrated in 50 mM phosphate 437 
buffer at pH 7.0. The mixture was then vortexed and subjected to freeze and thaw 438 
cycles with vortexing and pipetting. Concentrated protein stocks and D2O were then 439 
added to the clear bicelle solution to a final concentration of 8%(w/v) lipids, 0.2 mM 440 
protein and 10% D2O. 441 
Further details about bicelle preparation protocols are described in Perez et al. 442 
(Perez et al., 20132). 443 
 444 
Reagents and chemicals 445 
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Synthetic peptides SH4 (residues 2-19, GSNKSKPKDASQRRRSLE) and PPP (Ac-446 
VSLARRPLPPLP-OH) were synthesized and purified by GenScript, USA.  447 
IPTG was purchased to Melford, UK; MTSL paramagnetic tag was purchased to 448 
Toronto Research Chemicals, Canada; DHPC and DMPG lipids were purchased to 449 
Avanti Polar Lipids, USA; the rest of salts and reagents were purchased to Sigma. 450 
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 568 
FIGURE LEGENDS 569 
 570 
Figure 1. Domain structure and amino acid sequence of USrc-SH3 of human c-571 
Src. (A) Domain structure of c-Src and regulatory interactions. Classical interactions 572 
of the SH2 domain with phosphotyrosine, the SH3 domain with a proline rich 573 
connector linking SH2 and SH1, and of SH4 with lipids are indicated in black. New 574 
interactions reported here are shown in red. (B) Residues 1-85 (SH4 and Unique 575 
domains) are shown in black. Residues 86-150 (SH3 domain) are shown in grey. 576 
The secondary structure according to Wang et al., 2001 is represented on top of the 577 
sequence. c-Src SH3 residues that are in direct contact with the core sequences of 578 
poly-proline ligand (Feng et al., 1995) are highlighted in brown. SH4-domain = red; 579 
Unique Lipid Binding Region (ULBR) = light-blue; RT-loop = green; nSrc-loop = dark 580 
blue; distal-loop = gold. The SH4 domain is divided in two sub-domains (see text for 581 
details). (C) Crystal structure of the SH3 domain of human c-Src (Protein Data Bank 582 
ID code 4HXJ). The color code is the same as in part B.  583 
 584 
Figure 2. SH3 inter-domain interactions. (A-D) Combined absolute value 1H-15N 585 
NMR chemical shift changes between linked and isolated domains. (A and C) USrc-586 
SH3 versus USrc at 278 K. (B and D) USrc-SH3 versus SH3 at 298 K. C and D were 587 
measured in the presence of 1 equivalent of PPP while no SH3-ligand was added in 588 
A and B. K5* Δδ value is 0.18 ppm (A and C) and V86* Δδ value is 0.14 ppm (B) and 589 
0.13 ppm (D). V114* Δδ value is 0.12 ppm. All spectra were measured at pH 7.0 and 590 
at a protein concentration of 0.2 mM. Combined NH chemical shift differences (Δδ) 591 
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were computed as in equation 1 (see Experimental Procedures). Grey circles 592 
indicate proline residues. The dashed line represents one standard deviation. SH3 593 
residues perturbed by the presence of USrc in the absence (E) and in the presence 594 
of PPP (F) are highlighted on the SH3 structure (PDB entry 4HXJ). 595 
 596 
Figure 3. SH3-SH4 domains interaction. (A) Combined absolute value 1H-15N 597 
NMR chemical shift changes between SH3 domain alone and in presence of a 10-598 
fold excess of SH4 peptide. (B) SH3 residues perturbed by the presence of a 10-fold 599 
excess of SH4 peptide are highlighted on the SH3 structure (PDB entry 4HXJ). (C) 600 
1H-15N NMR chemical shift perturbations between SH3-PPP complex and SH3-PPP 601 
in presence of a 10-fold excess of SH4 peptide. Combined NH chemical shift 602 
differences (Δδ) were computed as in equation 1 (see Experimental Procedures). 603 
Grey circles indicate proline residues. The dashed line represents one standard 604 
deviation. 605 
 606 
Figure 4. ULBR mutations partially affect inter-domain interactions. Combined 607 
absolute value 1H-15N NMR chemical shift changes between linked and isolated 608 
domains measured at pH 7.0 (A) USrc-SH3-AAA versus USrc-AAA at 278 K, K5* 609 
Δδvalue is 0.11 ppm (B) USrc-SH3-AAA versus SH3 at 298 K. V86* Δδ value is 610 
0.14 ppm. Proline residues are shown as grey circles. Dashed lines correspond to 611 
one standard deviation. 612 
 613 
Figure 5. PRE experiments in spin-labeled USrc-SH3 constructs. Intensity ratios 614 
of NH cross-peaks from MTSL-labeled A59C-USrc-SH3 WT (A) and A59C-USrc-615 
SH3-AAA mutant (B), between paramagnetic (oxidized) and diamagnetic (reduced) 616 
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forms. The most affected regions in the SH3 domain are highlighted. M = MTSL; 617 
grey circles indicate proline residues. 618 
 619 
Figure 6. Effect of AAA mutation on long range interactions within the Unique 620 
domain. Intensity ratios of NH cross-peaks from MTSL-labeled A59C-USrc WT (A), 621 
A59C-USrc-AAA mutant (B) between paramagnetic (oxidized) and diamagnetic 622 
(reduced) forms. The grey line corresponds to the theoretical PREs computed from 623 
the random-coil definition (see Experimental Procedures). M = MTSL; grey circles 624 
indicate prolines. 625 
 626 
Figure 7. Effect of the Poly-Proline peptide on the SH3-lipid interaction. (A) 627 
Combined 1H-15N chemical shift changes of USrc-SH3 induced by the presence of 628 
8% w/v of DHPC/DMPG bicelles. (B) Combined 1H-15N chemical shift changes 629 
between USrc-SH3 WT construct in presence of PPP and in presence of PPP + 630 
DHPC/DMPG bicelles. (C) Combined 1H-15N chemical shift perturbations between 631 
USrc-SH3 WT construct in presence of DHPC/DMPG bicelles and in presence of 632 
DHPC/DMPG bicelles + PPP (only USrc residues are shown). (D) Combined 1H-15N 633 
chemical shift changes between USrc-SH3 WT construct in presence of 634 
DHPC/DMPG bicelles and in presence of DHPC/DMPG bicelles + PPP (only SH3 635 
residues are shown). Notice the expanded Δδ scale associated to PPP binding. 636 
Arrows mark SH3 residues known to be directly interacting with PPP (long for the 637 
core, short for additional regions). Grey circles indicate proline residues. The dashed 638 
line represents one standard deviation. See also Figure S2. 639 
 640 
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Figure 8. Cartoon models showing SH4-Unique-SH3 interactions. The grey 641 
sphere represents the SH3 domain. The black line corresponds to the Unique 642 
domain, which is connected to the back of the SH3 domain. Residues or regions 643 
experimentally detected to be involved in interactions are indicated. The yellow oval 644 
represents the lipid bicelle (not to scale). (A) USrc-SH3 WT. Residues E60 and N68 645 
are located at the beginning and at the end of the ULBR respectively. (B) USrc-SH3 646 
AAA. Most of the inter-domain contacts outside the ULBR are retained. This 647 
mutation also affects the conformational space sampled by USrc. (C) USrc-SH3-PPP 648 
complex. SH3-Unique contacts are abolished while N-SH4-SH3 interaction is 649 
maintained. (D) USrc-SH3 in presence of lipids. SH4, ULBR (USrc) and the RT and 650 
nSrc loops of SH3 are involved in lipid binding. USrc-SH3 contacts are conserved. 651 
(E) USrc-SH3-PPP complex in presence of lipids. Direct SH3-lipids interaction is 652 
abolished. ULBR and SH4 interact with lipids. The SH4-SH3 interaction is retained. 653 
 654 
Table 1.  Truncated forms of c-Src used in this study. 655 
Acronym Residues Description Modifications 
USrc-SH3 WT 1-150         SH4-Unique-SH3 GAa at N-terminus 
USrc-SH3-AAA 1-150 SH4-Unique-SH3 
GA at N-terminus 
63LFG65 - 63AAA65 
USrc-SH3-WT-MTSL 1-150 SH4-Unique-SH3 
GA at N-terminus 
A59C - MTSL 
USrc-SH3-AAA-MTSL 1-150 SH4-Unique-SH3 
GA at N-terminus 
63LFG65 - 63AAA65 
A59C - MTSL 
USrc WT 1-85 SH4-Unique STb at C-terminus  
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USrc-AAA 1-85 SH4-Unique 
ST at C-terminus 
63LFG65 - 63AAA65 
USrc-WT-MTSL 1-85 SH4-Unique 
ST at C-terminus 
A59C - MTSL 
USrc-AAA-MTSL 1-85 SH4-Unique 
ST at C-terminus 
63LFG65 - 63AAA65 
A59C - MTSL 
SH3 86-150 SH3 GA at N-terminus 
SH4 peptide 2-19 SH4 - 
a Residues located before Methionine 1 after TEV cleavage. 656 
b ST= Strep-tag (SAWSHPQFEK). 657 
 658 
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SUPPLEMENTAL FIGURES 
 
Figure S1. USrc-SH3-lipid interaction. (A,B) Combined 1H-15N chemical 
shift changes of USrc-SH3 WT (A) and USrc-SH3-AAA mutant (B) induced by 
the presence of 8% w/v of DHPC/DMPG bicelles. Grey circles indicate proline 
residues. The dashed line represents one standard deviation. 
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 Figure S2. Effect of the Poly-Proline peptide on the SH3-lipid interaction. 
(A,B) Expansion of the T99 and S128 cross-peaks from 1H-15N HSQC NMR 
spectra of USrc-SH3 WT construct alone (red), in presence of negatively 
charged DHPC/DMPG bicelles (blue), in presence of PPP (black) and in 
presence of DHPC/DMPG and PPP (green). (C,D) Expansion of USrc-SH3 
spectra showing residue A55 (UD) perturbed in the presence of DHPC/DMPG 
bicelles. This residue is successively affected by the addition of the VSL12 
peptide resulting in the dissociation from the USrc-SH3-lipids complex to its 
unbound form. 
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 Figure S3. USrc-SH3-AAA inter-domain interaction in the presence of 
PPP. (A) Combined absolute value 1H-15N NMR chemical shift changes 
between linked and isolated domains in the presence of 1 equivalent of PPP. 
(A) USrc-SH3-AAA versus USrc-AAA at 278 K. (B) USrc-SH3-AAA versus 
SH3 at 298 K. K5* value is 0.14 ppm (A) and V86* value is 0.13 ppm 
(B). V114* value is 0.11 ppm. All spectra were measured at pH 7.0 and at 
a protein concentration of 0.2 mM. Combined NH chemical shift differences 
(Δδ) were computed as in equation 1 (see Experimental Procedures). Gray 
circles indicate proline residues. The dashed line represents one standard 
deviation. (C) Expansion of A79 (Unique domain, hinge region) A52 (Unique 
domain) and A11 (SH4 domain) cross-peaks from 1H-15N HSQC NMR spectra 
of USrc-SH3-AAA construct alone (red), USrc-AAA alone (black) and USrc-
SH3-AAA in presence of PPP (green).  
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SUPPLEMENTAL TABLE 
Table S1. v-Src sequence alignment. Multiple sequence alignment of the 
several strains of v-Src showing the first 177 residues. Human c-Src (Uniprot 
Entry P12931) USrc-SH3 sequence is shown in red as comparison. ULBR is 
highlighted in light blue. RT-loops are shown in green. UniProt entries 
correspond respectively to: K7RW18 - CANFA = V-src sarcoma Schmidt-
Ruppin A-2 viral oncogene-like protein (DOG canis familiaris); P15054 - 
SRC_AVIS2 = Tyrosine-protein kinase transforming protein Src (Avian 
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sarcoma virus) (strain PR2257); P14085 - SRC_AVIST = Tyrosine-protein 
kinase transforming protein Src (Avian sarcoma virus) (strain S2); P00524 - 
SRC_RSVSA = Tyrosine-protein kinase transforming protein Src Avian 
leukosis virus RSA (RSV-SRA) (Rous sarcoma virus (strain Schmidt-Ruppin 
A); P00525 - SRC_AVISR = Tyrosine-protein kinase transforming protein Src 
(Avian sarcoma virus (strain rASV1441); Q60567 - 9RETR = V-3src-1 protein 
(Rous sarcoma virus); P25020 - SRC_RSVH1 = Tyrosine-protein kinase 
transforming protein Src (Rous sarcoma virus (strain H-19); Q64994 - 9RETR 
= (Schmidt-Ruppin D strain) v-src (Rous sarcoma virus); P63185 - 
SRC_RSVSE = Tyrosine-protein kinase transforming protein Src (Rous 
sarcoma virus (strain Schmidt-Ruppin E) (RSV-SR-E); O93080 - 9RETR = 
TsUP1 Src (Rous sarcoma virus); O92806 -9RETR = P60 src (Rous sarcoma 
virus); P00526 - SRC_RSVP = Tyrosine-protein kinase transforming protein 
Src (Rous sarcoma virus (strain Prague C) (RSV-PrC); Q85477 - 9RETR = 
Src (Rous sarcoma virus); O92957 - RSVSB = Src tyrosine kinase (Rous 
sarcoma virus (strain Schmidt-Ruppin B) (RSV-SRB); Q64993 - RSVSR = 
Tyrosine kinase (Rous sarcoma virus - Schmidt-Ruppin D); Q07461 - 9RETR 
= Src protein (Rous sarcoma virus); Q86362 - 9RETR = Pp62v (Rous 
sarcoma virus); Q86363 - 9RETR = Pp62v (Rous sarcoma virus). Sequence 
alignment was generated using Clustal Omega (EMBL-EBI). 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Graphical Abstract
Click here to download high resolution image
